EHA 2025: First-in-Class BTK Degrader Drives Strong Responses in R/R CLL/SLL

During EHA 2025, Professor Lydia Scarfò from San Raffaele Hospital, Milan, Italy, presented updated data on the efficacy and safety of a potential first-in-class protein degrader in patients with heavily pretreated relapsed or refractory CLL/SLL. In this MEDtalk, Professor Scarfò emphasizes the clear need for therapies with novel mechanisms of action to achieve sustained disease control.